surmount-1 tirzepatide weight loss results trial obesity without diabetes for Obesity: Highlights from the going from 2.5 to 5 – Presented at #ECO2025: In the – SURMOUNT-1: Adults achieve weight loss

Limitations to use of salt substitutes include low availability in the United States of potassium-enriched salt substitutes in the ratios studied to date, potential concerns over taste, and the potential for hyperkalemia in individuals with CKD and those using drugs that reduce potassium excretion (eg, potassium-sparing diuretics)

Novo Nordisk was the pioneer--winning a 2014 FDA-approval for liraglutide (Saxenda) as an obesity treatment, formulated as a once-daily subcutaneous injection

Moreover, the model recapitulated circulating biomarker responses to semaglutide observed in people with MASH

At En Vogue IV Therapy & Wellness, we stay informed about the latest research to offer our patients up-to-date advice and care

Oprea AD, Ostapenko LJ, Sweitzer B, Selzer A, Irizarry-Alvarado JM, Hurtado Andrade MD, et al

Theyve got some rules to make sure these treatments are used the right way, which is key to avoiding any potential health risks and getting the most out of the meds